

Resource Summary Report

Generated by [RRID](#) on Aug 19, 2026

pDONR223-ERBB3

RRID:Addgene_23874

Type: Plasmid

Proper Citation

RRID:Addgene_23874

Plasmid Information

URL: <http://www.addgene.org/23874>

Proper Citation: RRID:Addgene_23874

Insert Name: ERBB3

Organism: Homo sapiens

Bacterial Resistance: Spectinomycin

Defining Citation: [PMID:21107320](#)

Vector Backbone Description: Backbone Marker:Invitrogen; Backbone Size:5005; Vector Backbone:pDONR223; Vector Types:Gateway Cloning; Bacterial Resistance:Spectinomycin

Comments: The ORF has no Stop codon. This design enables easy recombination into a destination vector to add an epitope tag of choice and Stop codon to the ORF. Do NOT use this plasmid directly for transfections. A set of 4 custom lentiviral vectors is available (pLX301 (<http://www.addgene.org/25895/>) , pLX302 (<http://www.addgene.org/25896/>) , pLX303 (<http://www.addgene.org/25897/>) , pLX304 (<http://www.addgene.org/25890/>)) to be used to express these ORFs in mammalian cells. These plasmids are not included in the kit and must be ordered separately.

Plasmid Name: pDONR223-ERBB3

Record Creation Time: 20220422T222106+0000

Record Last Update: 20260815T081225+0000

Ratings and Alerts

No rating or validation information has been found for pDONR223-ERBB3.

No alerts have been found for pDONR223-ERBB3.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pal AA, et al. (2023) Optogenetic clustering and membrane translocation of the BcLOV4 photoreceptor. Proceedings of the National Academy of Sciences of the United States of America, 120(32), e2221615120.

Campbell MR, et al. (2022) Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell reports, 38(5), 110291.

Campbell MR, et al. (2022) Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell reports, 38(5), 110285.

Stern YE, et al. (2022) Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells. Cellular and molecular life sciences : CMLS, 79(3), 178.

Al-Akhrass H, et al. (2021) A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance. Oncogene, 40(7), 1300.

Brand TM, et al. (2018) Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer research, 78(9), 2383.

Werbin JL, et al. (2017) Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane. Scientific reports, 7(1), 12150.

Brand TM, et al. (2017) Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(12), 3072.

Safavi S, et al. (2016) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget, 7(1), 433.

Fowler DK, et al. (2016) A MultiSite Gateway Toolkit for Rapid Cloning of Vertebrate Expression Constructs with Diverse Research Applications. PloS one, 11(8), e0159277.